FGFR
Fibroblast growth factor receptor
FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.
All Product Categories
-
FGFR Inhibitors
(321)
View all products
-
FGFR Agonists
(4)
View all products
-
FGFR Antagonist
(1)
View all products
-
FGFR Activators
(6)
View all products
-
FGFR Modulators
(3)
View all products
-
FGFR Degraders
(11)
View all products
-
FGFR Control
(1)
View all products
-
FGFR Ligands
(2)
View all products
-
FGFR Proteins
(97)
View all products
-
FGFR-1 Proteins
(20)
View all products
-
FGFR-2 Proteins
(31)
View all products
-
FGFR-3 Proteins
(26)
View all products
-
FGFR-4 Proteins
(18)
View all products
-
FGFR Related Products (390)
Related Products (390)
-
Recombinant Proteins (97)
-
Antibodies (11)
-
FGFR1 inhibitor-2
0 ImagesCat. No.: HY-139376CAS No.: 2410612-08-5FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC50 is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer.
-
FGFR-IN-4
0 ImagesCat. No.: HY-147619CAS No.: 2761211-49-6FGFR-IN-4 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20). FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Lavengratinib
0 ImagesCat. No.: HY-187793CAS No.: 2412854-49-8Synonyms: ABSK061Lavengratinib (ABSK061) is a FGFR2/FGFR3 inhibitor. Lavengratinib selectively inhibits FGFR2 and FGFR3 signaling pathways and reduces the risk of FGFR1-mediated hyperphosphatemia. Lavengratinib is suitable for research on advanced solid tumors (including cholangiocarcinoma, gastric cancer, non-small cell lung cancer, cervical cancer and urothelial cancer).
-
ARQ 069
0 ImagesCat. No.: HY-101544CAS No.: 1314021-57-2ARQ 069, an analog of ARQ 523, inhibits FGFR in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC50s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC50s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner.
-
FGFR1 inhibitor 7
0 ImagesCat. No.: HY-149486FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC50 of 2.1 μM.
-
FGFR2 N549K Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70823FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions.
-
2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose
0 ImagesCat. No.: HY-N13841CAS No.: 150302-84-42,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose is an FGFR3 and BRAF binder, and is an isovaleryl sucrose ester that can be found in Atractylodes japonica. 2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose shows low cytotoxicity against cancer cells.
-
FGFR4-IN-22
0 ImagesCat. No.: HY-170690CAS No.: 2922812-74-4FGFR4-IN-22 (compound 10f) is a potent inhibitor of FGFR4, with the IC50 of 5.4 nM. FGFR4-IN-22 serve as a potential lead compound targeting FGFR4 for anti-HCC agent development.
-
FGFR3-IN-6
0 ImagesCat. No.: HY-156790CAS No.: 2833703-72-1
-
Lenvatinib-d5
0 ImagesCat. No.: HY-10981S1Synonyms: E7080-d5
-
FGFR-IN-14
0 ImagesCat. No.: HY-162577CAS No.: 3047446-75-0FGFR-IN-14 (compound 10h) is a pan-FGFR inhibitor. FGFR-IN-14 inhibits FGFR1, FGFR2, FGFR3 and FGFR2 V564F gatekeeper mutant with IC50s of 46, 41, 99, and 62 nM, respectively. FGFR-IN-14 strongly suppresses NCI-H520 lung cancer cells, SNU-16 and KATO III gastric cancer cells proliferation with IC50s of 19, 59, and 73 nM, respectively.
-
FGFR-IN-2
0 ImagesCat. No.: HY-142921CAS No.: 2665665-09-6FGFR-IN-2 (compound 1) is a potent FGFR inhibitor with IC50s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research.
-
PRX-08066 maleate
0 ImagesCat. No.: HY-15472ACAS No.: 866206-55-5PRX-08066 maleate is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 maleate inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 maleate inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 maleate inhibits pulmonary vascular remodeling. PRX-08066 maleate can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET).
-
FGFR1 inhibitor-11
0 ImagesCat. No.: HY-158098CAS No.: 2157482-40-9FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity.
-
FGFR3-IN-10
0 ImagesCat. No.: HY-122833CAS No.: 2833703-74-3FGFR3-IN-10 is a FGFR3 inhibitor with an IC50 of <350 nM. FGFR3-IN-10 is applicable to research related to cancer, systemic sclerosis, fibrosis, achondroplasia, thanatophoric dysplasia, and Muenke syndrome.
-
FGFR2 Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS04915FGFR2 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
FGFR3-IN-4
0 ImagesCat. No.: HY-148778CAS No.: 2833706-13-9FGFR3-IN-4 is a selective FGFR3 inhibitor, with an IC50 value of less than 50 nM. FGFR3-IN-4 is at least 10 fold more selective for FGFR3 than for FGFR1.
-
Dabogratinib (GMP)
0 ImagesCat. No.: HY-159642GCAS No.: 2800223-30-5Synonyms: TYRA-300 (GMP)Dabogratinib (GMP) is the GMP-grade version of Dabogratinib (HY-159642). Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia.
-
IONIS-FGFR4Rx sodium scrambled negative control
0 ImagesCat. No.: HY-159691BIONIS-FGFR4Rx sodium scrambled negative control is the sequence scrambled negative control of IONIS-FGFR4Rx sodium.
-
Lenvatinib-15N,d4
0 ImagesCat. No.: HY-10981S2Purity: 98.01%Synonyms: E7080-15N,d4Lenvatinib-15N,d4 is 15N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
